News

Antibody selection is one of the most influential decisions made during early Lateral Flow Assay (LFA) development. Whether antibodies are sourced commercially or developed as part of a broader LFA development service, the choices made at this stage directly affect assay sensitivity, specificity, reproducibility and long-term manufacturability. Applying a structured, risk based approach to antibody evaluation can significantly reduce technical and commercial challenges later

Lateral Flow Assays (LFAs) may look simple, but successful development is far from straightforward. Behind reliable, consistent performance lies careful control of multiple interacting variables that can otherwise introduce hidden risk. Too often, development challenges surface late, when changes are costly, timelines slip and verification efforts fail. The difference between a smooth path to market and repeated re-design frequently comes down to early technical decisions an